InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,180.74
(
1.03%
)
US TECH 100
17,611.60
(
0.01%
)
Dow Jones
38,852.27
(
0.46%
)
Brent Oil
83.21
(
-0.32%
)
Bitcoin
64,212.86
(
1.66%
)
Post# of 2338331
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

WALL STREET KID

Send PM Follow Ignore
Followers 714
Posts 21735
Boards Moderated 4
Alias Born 04/30/2007

WALL STREET KID

Member Level

Re: None

Wednesday, 02/19/2020 1:42:03 AM

Wednesday, February 19, 2020 1:42:03 AM

Post# of 2338331
GNPX 21.07m NRBO 7.83m floats killer charts Biotec Nasdaq tickers, Charles Astor plays. Killer charts on both plays

Genprex is almost done stage 3 on new diabetes drug as well as has a Cancer drug in the pipeline

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on multimodal, disease-modifying therapies for neurodegenerative diseases, today reported that the previously announced merger between NeuroBo Pharmaceuticals, Inc., ("NeuroBo") and Gemphire Therapeutics (Nasdaq: GEMP) closed on December 31, 2019. The new combined company, known as NeuroBo Pharmaceuticals began trading on the Nasdaq exchange under the ticker "NRBO" on December 31, 2019. NeuroBo will focus on advancing the company’s clinical-stage pipeline for neurodegenerative diseases.

Please do your own DD, do not base your investment decisions on my or anyone else's post

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up